Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex

Promising targets for radiosensitization

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Radiotherapy plays a central part in cancer treatment, and use of radiosensitizing agents can greatly enhance this modality. Although studies have shown that several chemotherapeutic agents have the potential to increase the radiosensitivity of tumor cells, investigators have also studied a number of molecularly targeted agents as radiosensitizers in clinical trials based on reasonably promising pre-clinical data. Recent intense research into the DNA damage-signaling pathway revealed that ataxia-telangiectasia mutated (ATM) and the Mrell-Rad50-NBSl (MRN) complex play central roles in DNA repair and cell cycle checkpoints and that these molecules are promising targets for radiosensitization. Researchers recently developed three ATM inhibitors (KU-55933, CGK733, and CP466722) and an MRN complex inhibitor (mirin) and showed that they have great potential as radiosensitizers of tumors in preclinical studies. Additionally, we showed that a telomerase-dependent oncolytic adenovirus that we developed (OBP-301 [telomelysin]) produces profound radiosensitizing effects by inhibiting the MRN complex via the adenoviral ElB55kDa protein. A recent Phase I trial in the United States determined that telomelysin was safe and well tolerated in humans, and this agent is about to be tested in combination with radiotherapy in a clinical trial based on intriguing preclinical data demonstrating that telomelysin and ionizing radiation can potentiate each other. In this review, we highlight the great potential of ATM and MRN complex inhibitors, including telomelysin, as radiosensitizing agents.

Original languageEnglish
Pages (from-to)83-92
Number of pages10
JournalActa Medica Okayama
Volume66
Issue number2
Publication statusPublished - 2012

Fingerprint

Radiation-Sensitizing Agents
Ataxia Telangiectasia
Radiotherapy
Tumors
Cells
Research Personnel
Clinical Trials
Neoplasms
Oncology
Telomerase
Radiation Tolerance
DNA
Ionizing radiation
Cell Cycle Checkpoints
Ionizing Radiation
Adenoviridae
DNA Repair
DNA Damage
Repair
Molecules

Keywords

  • Adenovirus
  • ATM (ataxia-telangiectasia mutated)
  • ElB55kDa
  • MRN (Mrell-Rad50-NBSl) complex
  • Radiosensitization

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex : Promising targets for radiosensitization. / Kuroda, Shinji; Urata, Yasuo; Fujiwara, Toshiyoshi.

In: Acta Medica Okayama, Vol. 66, No. 2, 2012, p. 83-92.

Research output: Contribution to journalArticle

@article{02647c15f60f481f808727b48b047366,
title = "Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex: Promising targets for radiosensitization",
abstract = "Radiotherapy plays a central part in cancer treatment, and use of radiosensitizing agents can greatly enhance this modality. Although studies have shown that several chemotherapeutic agents have the potential to increase the radiosensitivity of tumor cells, investigators have also studied a number of molecularly targeted agents as radiosensitizers in clinical trials based on reasonably promising pre-clinical data. Recent intense research into the DNA damage-signaling pathway revealed that ataxia-telangiectasia mutated (ATM) and the Mrell-Rad50-NBSl (MRN) complex play central roles in DNA repair and cell cycle checkpoints and that these molecules are promising targets for radiosensitization. Researchers recently developed three ATM inhibitors (KU-55933, CGK733, and CP466722) and an MRN complex inhibitor (mirin) and showed that they have great potential as radiosensitizers of tumors in preclinical studies. Additionally, we showed that a telomerase-dependent oncolytic adenovirus that we developed (OBP-301 [telomelysin]) produces profound radiosensitizing effects by inhibiting the MRN complex via the adenoviral ElB55kDa protein. A recent Phase I trial in the United States determined that telomelysin was safe and well tolerated in humans, and this agent is about to be tested in combination with radiotherapy in a clinical trial based on intriguing preclinical data demonstrating that telomelysin and ionizing radiation can potentiate each other. In this review, we highlight the great potential of ATM and MRN complex inhibitors, including telomelysin, as radiosensitizing agents.",
keywords = "Adenovirus, ATM (ataxia-telangiectasia mutated), ElB55kDa, MRN (Mrell-Rad50-NBSl) complex, Radiosensitization",
author = "Shinji Kuroda and Yasuo Urata and Toshiyoshi Fujiwara",
year = "2012",
language = "English",
volume = "66",
pages = "83--92",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "2",

}

TY - JOUR

T1 - Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex

T2 - Promising targets for radiosensitization

AU - Kuroda, Shinji

AU - Urata, Yasuo

AU - Fujiwara, Toshiyoshi

PY - 2012

Y1 - 2012

N2 - Radiotherapy plays a central part in cancer treatment, and use of radiosensitizing agents can greatly enhance this modality. Although studies have shown that several chemotherapeutic agents have the potential to increase the radiosensitivity of tumor cells, investigators have also studied a number of molecularly targeted agents as radiosensitizers in clinical trials based on reasonably promising pre-clinical data. Recent intense research into the DNA damage-signaling pathway revealed that ataxia-telangiectasia mutated (ATM) and the Mrell-Rad50-NBSl (MRN) complex play central roles in DNA repair and cell cycle checkpoints and that these molecules are promising targets for radiosensitization. Researchers recently developed three ATM inhibitors (KU-55933, CGK733, and CP466722) and an MRN complex inhibitor (mirin) and showed that they have great potential as radiosensitizers of tumors in preclinical studies. Additionally, we showed that a telomerase-dependent oncolytic adenovirus that we developed (OBP-301 [telomelysin]) produces profound radiosensitizing effects by inhibiting the MRN complex via the adenoviral ElB55kDa protein. A recent Phase I trial in the United States determined that telomelysin was safe and well tolerated in humans, and this agent is about to be tested in combination with radiotherapy in a clinical trial based on intriguing preclinical data demonstrating that telomelysin and ionizing radiation can potentiate each other. In this review, we highlight the great potential of ATM and MRN complex inhibitors, including telomelysin, as radiosensitizing agents.

AB - Radiotherapy plays a central part in cancer treatment, and use of radiosensitizing agents can greatly enhance this modality. Although studies have shown that several chemotherapeutic agents have the potential to increase the radiosensitivity of tumor cells, investigators have also studied a number of molecularly targeted agents as radiosensitizers in clinical trials based on reasonably promising pre-clinical data. Recent intense research into the DNA damage-signaling pathway revealed that ataxia-telangiectasia mutated (ATM) and the Mrell-Rad50-NBSl (MRN) complex play central roles in DNA repair and cell cycle checkpoints and that these molecules are promising targets for radiosensitization. Researchers recently developed three ATM inhibitors (KU-55933, CGK733, and CP466722) and an MRN complex inhibitor (mirin) and showed that they have great potential as radiosensitizers of tumors in preclinical studies. Additionally, we showed that a telomerase-dependent oncolytic adenovirus that we developed (OBP-301 [telomelysin]) produces profound radiosensitizing effects by inhibiting the MRN complex via the adenoviral ElB55kDa protein. A recent Phase I trial in the United States determined that telomelysin was safe and well tolerated in humans, and this agent is about to be tested in combination with radiotherapy in a clinical trial based on intriguing preclinical data demonstrating that telomelysin and ionizing radiation can potentiate each other. In this review, we highlight the great potential of ATM and MRN complex inhibitors, including telomelysin, as radiosensitizing agents.

KW - Adenovirus

KW - ATM (ataxia-telangiectasia mutated)

KW - ElB55kDa

KW - MRN (Mrell-Rad50-NBSl) complex

KW - Radiosensitization

UR - http://www.scopus.com/inward/record.url?scp=84864746641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864746641&partnerID=8YFLogxK

M3 - Article

VL - 66

SP - 83

EP - 92

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 2

ER -